Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in children and adolescents with moderate-to-severe plaque psoriasis
NL-OMON45268Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in plaque psoriasis (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: PASI 75 at Week 12 and sPGA (0,1) at Week 12. Started Nov 2017; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON45268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45268.